Laurie Doyle

Investor Relations Contact at GPC Biotech, Inc.

Health Technology

Retail Trade

Profile

Ms. Laurie Doyle is a Director-Corporate Communications at GPC Biotech, Inc. and a Director-Corporate Communications at Transgene SA. Ms. Doyle was previously employed as Senior Director-US Investor Relations by Agennix AG.

Laurie Doyle active positions

Companies	Position	Start
GPC Biotech, Inc. GPC Biotech, Inc. Drugstore ChainsRetail Trade GPC Biotech, Inc. discovers and develops anticancer drugs through discovery technologies and development approaches. It is a mechanism-based drug discovery and development company focused on treatments for cancer and fungal infections. The company is a wholly owned subsidiary of GPC Biotech AG. GPC Biotech was founded in 1992 and is located in Waltham, MA.	Investor Relations Contact	-

All active positions of Laurie Doyle

Former positions of Laurie Doyle

Companies	Position	End
TRANSGENE	Public Communications Contact	-
AGENNIX AG	Public Communications Contact	-

See the detail of Laurie Doyle's experience

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Laurie Doyle's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	1
TRANSGENE	Health Technology

Private companies	2
GPC Biotech, Inc. GPC Biotech, Inc. Drugstore ChainsRetail Trade GPC Biotech, Inc. discovers and develops anticancer drugs through discovery technologies and development approaches. It is a mechanism-based drug discovery and development company focused on treatments for cancer and fungal infections. The company is a wholly owned subsidiary of GPC Biotech AG. GPC Biotech was founded in 1992 and is located in Waltham, MA.	Retail Trade
Agennix AG Agennix AG BiotechnologyHealth Technology Agennix AG was a pharmaceutical company, which engaged in the development of protein-based drugs for oncology, asthma and wound healing. Its clinical development programs included oral talactoferrin alfa and RGB-286638. The company was founded in 1993 and was headquartered in Heidelberg, Germany.	Health Technology